MA53237A - Traitement d'un lymphome folliculaire récidivant - Google Patents

Traitement d'un lymphome folliculaire récidivant

Info

Publication number
MA53237A
MA53237A MA053237A MA53237A MA53237A MA 53237 A MA53237 A MA 53237A MA 053237 A MA053237 A MA 053237A MA 53237 A MA53237 A MA 53237A MA 53237 A MA53237 A MA 53237A
Authority
MA
Morocco
Prior art keywords
recurring
treatment
follicular lymphoma
follicular
lymphoma
Prior art date
Application number
MA053237A
Other languages
English (en)
Inventor
Daniel P Gold
Original Assignee
Mei Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mei Pharma Inc filed Critical Mei Pharma Inc
Publication of MA53237A publication Critical patent/MA53237A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA053237A 2018-08-14 2019-08-13 Traitement d'un lymphome folliculaire récidivant MA53237A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862718926P 2018-08-14 2018-08-14
US201962836507P 2019-04-19 2019-04-19

Publications (1)

Publication Number Publication Date
MA53237A true MA53237A (fr) 2021-06-23

Family

ID=69525835

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053237A MA53237A (fr) 2018-08-14 2019-08-13 Traitement d'un lymphome folliculaire récidivant

Country Status (14)

Country Link
US (1) US20210196725A1 (fr)
EP (1) EP3836936A4 (fr)
JP (1) JP2021534116A (fr)
KR (1) KR20210043637A (fr)
CN (1) CN112839659A (fr)
AU (1) AU2019321526A1 (fr)
BR (1) BR112021002734A2 (fr)
CA (1) CA3109377A1 (fr)
IL (1) IL280721A (fr)
MA (1) MA53237A (fr)
MX (1) MX2021001765A (fr)
SG (1) SG11202101417XA (fr)
TW (1) TW202021593A (fr)
WO (1) WO2020036997A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2691384B1 (fr) 2011-03-28 2016-10-26 MEI Pharma, Inc. (aralkylamino- et heteroaralkylamino)-pyrimidinyl- et 1,3,5-triazinyl-benzimidazoles substitues sur la position alpha, compositions pharmaceutiques les contenant et ces composes destines a etre utilises dans le traitement des maladies proliferatives
CA3063976A1 (fr) 2017-05-23 2018-11-29 Mei Pharma, Inc. Polytherapie
WO2019036489A1 (fr) 2017-08-14 2019-02-21 Mei Pharma, Inc. Polythérapie

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2919869B1 (fr) * 2007-08-09 2009-09-25 Sanofi Aventis Sa Nouveaux derives de n, n'-2,4-dianilinopyrimidines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
EP2691384B1 (fr) * 2011-03-28 2016-10-26 MEI Pharma, Inc. (aralkylamino- et heteroaralkylamino)-pyrimidinyl- et 1,3,5-triazinyl-benzimidazoles substitues sur la position alpha, compositions pharmaceutiques les contenant et ces composes destines a etre utilises dans le traitement des maladies proliferatives
CN114366746A (zh) * 2012-08-09 2022-04-19 细胞基因公司 使用氧代异吲哚化合物治疗癌症
MA38462A1 (fr) * 2013-04-08 2017-10-31 Bayer Pharma AG Utilisation de 2,3-dihydroimidazo[1,2-c]quinazolines substituées pour le traitement de lymphomes
DK3262071T3 (da) * 2014-09-23 2020-06-15 Hoffmann La Roche Fremgangsmåde til anvendelse af anti-CD79b-immunkonjugater
MX390121B (es) * 2016-09-19 2025-03-20 Mei Pharma Inc Combinaciones de un inhibidor de btk y un inhibidor de pi3k para tratar neoplasias malignas hematológicas.
WO2019036489A1 (fr) * 2017-08-14 2019-02-21 Mei Pharma, Inc. Polythérapie

Also Published As

Publication number Publication date
CA3109377A1 (fr) 2020-02-20
EP3836936A4 (fr) 2022-05-18
IL280721A (en) 2021-03-25
WO2020036997A1 (fr) 2020-02-20
KR20210043637A (ko) 2021-04-21
BR112021002734A2 (pt) 2021-07-20
CN112839659A (zh) 2021-05-25
AU2019321526A1 (en) 2021-03-25
EP3836936A1 (fr) 2021-06-23
SG11202101417XA (en) 2021-03-30
MX2021001765A (es) 2021-04-19
TW202021593A (zh) 2020-06-16
JP2021534116A (ja) 2021-12-09
US20210196725A1 (en) 2021-07-01

Similar Documents

Publication Publication Date Title
EP4041212C0 (fr) Inhibiteurs de mek pour le traitement d'infections à hantavirus
EP3641829A4 (fr) Promédicament d'interféron pour le traitement du cancer
MA45192A (fr) Traitement d'association
EP3930600A4 (fr) Dispositifs et procédés de traitement d'oedème
EP3979967A4 (fr) Systèmes et méthodes de traitement d'oedème
MA45037A (fr) Polythérapie à base d'arnm pour le traitement du cancer
MA50849A (fr) Substances et procédés pour le traitement d'hémoglobinopathies
EP3813806A4 (fr) Méthodes de traitement d'un dysfonctionnement mitochondrial
EP3621600A4 (fr) Procédés pour le traitement d'un glioblastome récurrent (rgbm)
EP3625971A4 (fr) Traitement d'audio spatial
MA43170A (fr) Association d'un inhibiteur de bcl-2 et d'un inhibiteur de mek pour le traitement du cancer
IL287704A (en) Use of cannabidiol in the treatment of tuberous sclerosis complex
MA52627A (fr) Traitement du cancer
MA43825A (fr) Schémas posologiques pour le traitement d'infections fongiques
EP3773221A4 (fr) Traitement pour l'hydrocéphalie
EP3893874A4 (fr) Traitement combiné à base de crénolanib
EP3716966A4 (fr) Compositions d'alpha-cétoacides pour le traitement de l'hypoalbuminémie
MA49576A (fr) Compositions et méthodes pour le traitement d'infections fongiques
EP3735209A4 (fr) Traitement de la progression de la myopie
EP3630080A4 (fr) Utilisation d'inhibiteurs de ezh2 pour le traitement du cancer
EP3781584A4 (fr) Promédicaments de 4'-thio-nucléotide et de nucléoside pour le traitement du cancer
EP3763327A4 (fr) Dispositif de traitement d'aorte
EP4021858A4 (fr) Traitement d'azoles
EP3709968C0 (fr) Émulsions destinés au traitement d'infections vaginales
EP3829619A4 (fr) Traitement de la mucopolysaccharidose iva